Drugs / OTX008
OTX008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01724320 | Feb 2012 → May 2013 | cancer | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTX008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01724320 ↗ |
| Known as | CALIXARENE 0118 | ChEMBL registry synonym — accepted as the source's own label CHEMBL221186 ↗ |
| Known as | KM-0118 | ChEMBL registry synonym — accepted as the source's own label CHEMBL221186 ↗ |
| Known as | PTX-008 | ChEMBL registry synonym — accepted as the source's own label CHEMBL221186 ↗ |
| Action | Inhibit | “OTX008 inhibits galectin-1 expression.” NCT01724320 ↗ |
| Modality | Small molecule | — CHEMBL221186 ↗ |
| Route | Subcutaneous | “OTX008 given daily without interruption, subcutaneously.” NCT01724320 ↗ |